This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
by Zacks Equity Research
Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Intellia (NTLA) Reports Positive Results for CRISPR Candidates
by Zacks Equity Research
Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
by Zacks Equity Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Incyte (INCY) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia (NTLA) Depreciates 27% Over a Month: Here's Why
by Zacks Equity Research
Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.